Q-omics provides the consensus-scored TUBA1B profile across patient tissues and cancer cell-line models. TUBA1B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TUBA1B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TUBA1B RNA expression shows 18,944 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where TUBA1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA1B survival associations across molecular data types. TUBA1B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA1B RNA expression–survival associations across cancer types. High TUBA1B expression shows unfavorable associations in MESO, KICH, LIHC, ACC, BLCA and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TUBA1B RNA expression.
This table summarizes TUBA1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBA1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA1B shows higher tumor expression in KIRC, KIRP, HNSC, LIHC, COAD and STAD. The KIRC box plot shows higher TUBA1B RNA expression in tumor versus normal tissue (log2 FC = +1.436, t-test p < 0.001).
This table shows molecular features associated with TUBA1B in patient tissues and cancer cell lines. In patient samples, TUBA1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
